Not available
Quote | Cytokinetics Incorporated (NASDAQ:CYTK)
Last: | $55.51 |
---|---|
Change Percent: | -0.39% |
Open: | $54.61 |
Close: | $55.51 |
High: | $55.65 |
Low: | $53.68 |
Volume: | 959,633 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Cytokinetics Incorporated (NASDAQ:CYTK)
2024-06-20 20:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian parti...
Message Board Posts | Cytokinetics Incorporated (NASDAQ:CYTK)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CYTK News Article - Cytokinetics Releases Inaugural Corporate Responsibility Report | whytestocks | investorshangout | 03/27/2023 7:46:03 PM |
Wow never seen a stock move up from | Cosa | investorshub | 12/14/2022 6:33:40 PM |
Sold at $41. | H2R | investorshub | 12/14/2022 3:01:42 PM |
Sorry to anyone holding here. I hope | Cosa | investorshub | 12/14/2022 3:54:15 AM |
AdCom: 8 to 3 against! | H2R | investorshub | 12/13/2022 11:29:31 PM |
News, Short Squeeze, Breakout and More Instantly...
Cytokinetics Incorporated Company Name:
CYTK Stock Symbol:
NASDAQ Market:
Cytokinetics Incorporated Website:
2024-06-20 20:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian parti...
2024-06-04 10:30:05 ET B. Riley analyst issues BUY recommendation for CYTK on June 4, 2024 08:58AM ET. The previous analyst recommendation was Buy. CYTK was trading at $49.018 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...